Jpn. J. Infect. Dis., 65 (5), 442-443, 2012
To see a printable version of the article in the Adobe file format, click this [PDF] link.
Kenji Ohnishi* and Fukumi Nakamura-Uchiyama
Department of Infectious Diseases, Tokyo Metropolitan Bokutoh General Hospital, Tokyo 130-8575, Japan
(Received May 2, 2012. Accepted July 23, 2012)
*Corresponding author: Mailing address: Department of Infectious Diseases, Tokyo Metropolitan Bokutoh General Hospital, 4-23-15 Kohtohbashi, Sumida City, Tokyo 130-8575, Japan. Tel: +81-3-3633-6151, Fax: +81-3-3633-6173, E-mail: このメールアドレスはスパムボットから保護されています。閲覧するにはJavaScriptを有効にする必要があります。
SUMMARY: Fifteen Japanese colitis patients, aged above 16 years old, infected with verotoxin-producing Escherichia coli O157 (VTEC O157) were divided into 2 treatment groups. Of the 15 patients, 6 (mean ± SD, 41.3 ± 19.0 years old) were treated with levofloxacin (LVFX), while the remaining 9 patients (32.0 ± 10.0 years old) were not treated with any antimicrobial agents. All patients complained of abdominal pain and bloody stool and were not administered antidiarrheals. Hemolytic uremic syndrome (HUS) did not develop in any of the 6 patients treated with LVFX, but developed in 1 of the 9 patients not treated with antimicrobial agents. No statistical difference was found in the occurrence rate of HUS between LVFX-treated patients and patients not treated with antimicrobial agents. Our results suggest that oral administration of LVFX is not associated with risk of HUS in hemorrhagic colitis patients aged above 16 years infected with VTEC O157.
